If you're going to make a difference, the story begins and ends with government.
From a small city on the Gulf of Bothnia, a Finnish company called Oura has quietly placed itself at the center of Washington's health and technology conversation. In a capital where influence is worn as much as it is spoken, Oura's smart ring has become both a status symbol and a lobbying instrument, as the company works to reshape federal regulation in its favor before the broader wearable market catches up. The story is one of a startup that understood, perhaps before anyone else, that in America the distance between a product and a policy is often shorter than it appears — and that the surest path to dominance runs through government.
- A Finnish company now controls two-thirds of the American smart ring market and has embedded itself so deeply in Washington that Pentagon officials, senators, and cabinet allies wear its product on their fingers.
- Oura is racing to rewrite the regulatory landscape before competitors can catch up, pushing the FDA and Congress to create a new 'digital health screener' classification that sidesteps the traditional medical device approval process.
- A data-sharing rumor involving Palantir triggered a social media backlash fierce enough that Oura's CEO had to respond on TikTok, exposing how quickly consumer trust can fracture when health data and government surveillance appear to intersect.
- The company is simultaneously suing Samsung, Reebok, and several smaller rivals for patent infringement, deploying the legal system as a market barrier in a move that critics note inverts the usual David-versus-Goliath logic of patent disputes.
- With $900 million raised, a Pentagon manufacturing deal in Texas, and a target of $1.5 billion in revenue this year, Oura is positioning itself for a valuation that could redefine what Nordic innovation means on the world stage.
A decade ago, Oura was little more than an idea in Oulu, a frozen Finnish city few Americans could locate on a map. Today, its rings sit on the fingers of Pentagon officials and members of Congress from both parties, and the company commands two-thirds of the U.S. smart ring market at an $11 billion valuation. U.S. sales surged 195 percent last year, and Oura captured most of that growth.
The ascent is not accidental. Oura has hired lobbyists with deep ties to both the Trump administration and the Senate health committee, and its CEO now visits Washington several times a year. The company has found an unlikely champion in Health Secretary Robert F. Kennedy Jr., who has made wearables a centerpiece of his Make America Healthy Again agenda, declaring that every American should own one by 2030.
Oura's central regulatory ambition is the creation of a new federal category called 'digital health screeners' — a classification that would let wearables flag potential health concerns without the lengthy approval process required of medical devices. After Oura's CEO published an op-ed in the Wall Street Journal arguing that policy had fallen behind technology, the FDA revised its rules within weeks. Oura is now asking Congress to codify those changes, and at least one House member is drafting legislation to do so.
The company's rise has not gone unchallenged. A rumor that Oura had shared user data with Palantir — the AI firm with deep ties to the Trump administration — ignited a social media firestorm, with users filming themselves discarding their rings. Hale responded directly on TikTok, insisting that only Pentagon contract data flows through Palantir and that consumer data remains private. Senator Bill Cassidy, whose former aide now lobbies for Oura, has nonetheless introduced legislation to hold wearable companies to the same privacy standards as medical records.
Oura is also fighting on a legal front, having won an International Trade Commission ruling against Indian and Chinese competitors and filed patent suits against Samsung and several others. Critics note the irony: unlike most patent battles, this one features the dominant player using litigation to shut out smaller rivals.
The company's ambitions reach further still. It has opened a U.S. manufacturing facility in Fort Worth in partnership with the Pentagon, raised over $900 million in its latest financing round, and set a revenue target of $1.5 billion for this year. In Finland, the hope is that Oura could become one of the rare Nordic startups to reach a $100 billion valuation — a milestone that would announce, to the world, that transformative technology can emerge from the far north.
A Finnish startup that barely existed a decade ago has become Washington's most coveted health accessory. Oura, a company from the frozen city of Oulu on the Gulf of Bothnia, now controls two-thirds of the American smart ring market. Its rings sit on the fingers of Pentagon officials, members of Congress from both parties, and increasingly, ordinary Americans who want to track their sleep, heart rate, and metabolic health. The company's valuation has climbed to $11 billion, up from $2.5 billion just four years ago. Last year alone, U.S. sales of smart rings jumped 195 percent, and Oura captured most of that growth.
But Oura's ascent in Washington is not accidental. The company has hired some of the capital's most connected lobbyists—including Hunter Morgen, who worked in Trump's first administration, and Christopher Gillott, a former deputy chief of staff to Senator Bill Cassidy, who chairs the Senate health committee. Oura's CEO Tom Hale now visits Washington once or twice a quarter. The company has signed pledges with the Department of Health and Human Services and the Centers for Medicare and Medicaid Services. It participates in White House roundtables. And it has found an unlikely champion in Robert F. Kennedy Jr., the health secretary who has made wearables central to his Make America Healthy Again movement, declaring that every American should own one by decade's end.
Oura's real prize, though, is regulatory. The company is pushing the FDA and Congress to create a new classification called "digital health screeners"—a category that would allow wearables to warn users about potential health problems without undergoing the lengthy approval process required of medical devices. In December, Oura's CEO published an op-ed in the Wall Street Journal arguing that federal policy had not kept pace with technology. Less than a month later, the FDA revised its rules to allow wearables to inform users when a health evaluation might be beneficial and to measure blood pressure and blood sugar without medical device approval. Now Oura is asking Congress to codify those changes and provide companies with clearer guidance on what claims are permissible. Representative Troy Balderson of Ohio, who chairs the House digital health caucus and wears a Garmin watch, says he is working on legislation to do exactly that.
The company's success in Washington reflects a broader shift in how the Trump administration approaches regulation. Rather than enforcing existing rules, the administration has embraced deregulation as a tool for spurring innovation. Oura has positioned itself as the beneficiary of that philosophy. "If you're going to make a difference in terms of access to any technology, the story begins and maybe ends with the government," Hale told Politico. "It just seemed really natural and obvious for us to start to build relationships there."
But Oura's rise has also sparked concern about data privacy and market competition. Last year, rumors that Oura had shared user data with Palantir, a software company that builds artificial intelligence tools for the Trump administration, sparked outrage on social media. Users posted videos of themselves throwing their rings away. Hale responded on TikTok, explaining that the company works with Palantir only through its Pentagon contract and that regular users' data remains private. The company says it complies with European data protection regulations and HIPAA standards in the United States. Still, lawmakers like Senator Cassidy have introduced legislation to hold wearable companies to the same data privacy standards that protect patient health records.
Oura is also waging an aggressive legal campaign against competitors. In September, the International Trade Commission ruled in favor of Oura, finding that India's Ultrahuman and China's RingConn had violated its patents and banning their products from the country. In November, Oura filed a complaint against Samsung, South Korea's most valuable company, along with Reebok, Zepp Health, and Nexxbase, alleging patent infringement. Samsung has filed a counter complaint. The dispute resembles the patent battle between Apple and Masimo over smartwatch technology, which ended with a jury awarding Masimo $634 million in damages. But there is a crucial difference: in the Apple-Masimo case, the company suing was the underdog. Here, Oura is the dominant player using the legal system to block smaller rivals. Members of Congress, including several who wear Oura rings themselves, have urged the U.S. Trade Representative to enforce the ITC decision against Oura's competitors, calling the patent violations a "direct threat" to the U.S. economy and national security.
Oura's ambitions extend far beyond the current moment. The company sold more than 5.5 million rings as of September, with more than half of those sales coming in the previous year. It expects to reach $1.5 billion in revenue this year, triple what it earned in 2024. In October, it raised over $900 million in financing, the largest venture capital round ever for a Finnish company. Last August, Oura announced its first U.S. manufacturing facility in Fort Worth, Texas, in partnership with the Pentagon. Hale declined to discuss what special products the military has requested, but he said the company decided to manufacture them domestically for security reasons. In Finland, venture capitalists and government officials are watching Oura's trajectory with hope. If the company continues its current growth, it could become one of the few Nordic startups to reach a $100 billion valuation—a milestone that would reshape how the world sees innovation from the Nordic region.
Notable Quotes
Every American should be sporting one by the end of the decade.— Robert F. Kennedy Jr., Health Secretary, on wearable devices
What we are seeing play out here is an incumbent using whatever they can to basically block competition from the market.— Mohit Kumar, CEO of Ultrahuman, on Oura's patent litigation strategy
The Hearth Conversation Another angle on the story
How did a company from a small Finnish city become the dominant player in a market that barely existed five years ago?
Oura got lucky with timing and design. The rings measure heart rate and blood oxygen more accurately on a finger than on a wrist. But the real breakthrough came when the Pentagon started using them to track military readiness after some fatal Navy collisions, and then during COVID when researchers found they could detect early illness. That gave the company credibility and scale.
But that doesn't explain Washington. Why are lawmakers wearing these rings and defending them in Congress?
Because Oura has made itself indispensable to the health agenda that matters right now. Kennedy wants wearables in every American's hand by 2030. Oura is the company that can deliver that vision. And the company has hired the right people to make sure lawmakers understand why that matters—people with connections, people who know how to move through the system.
The patent lawsuits against Samsung and others—is that about protecting innovation or crushing competition?
That's the question everyone is asking. Oura says it's defending intellectual property. But when you're the market leader suing smaller players, and members of Congress who wear your product are urging the government to enforce those lawsuits, it starts to look like something else. It looks like using the legal system to build a moat.
What about the data privacy concerns? The Palantir rumors spooked people.
They did. People were genuinely frightened that their intimate health data—sleep patterns, heart rate, menstrual cycles—was being fed into a government surveillance tool. Hale went on TikTok to reassure them. He said the Pentagon contract is separate, that regular users' data is private. But the fact that those rumors could spread so quickly tells you something: people don't fully trust where their data goes once they hand it over.
Is there a real regulatory problem that Oura is solving, or is this just a company that found a way to make regulation work for it?
Both, probably. The FDA's old categories—general wellness or full medical device—don't fit wearables well. A new category makes sense. But Oura is also the company that benefits most from that new category existing. So when you see the company lobbying for it, and then the FDA changes the rules, and then Congress considers codifying those changes, you have to ask: who wrote this script?